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Purpose: The purpose of this study was to conduct
qualitative participant interviews to provide context to
the meaningfulness of improvements in end points seen
in 2 large-scale Phase III sotagliflozin trials in
participants with type 1 diabetes.
Methods: Participants were eligible for an interview
if they had exited one of the clinical trials within the
previous 12 months. Participants were recruited by
investigators at the clinical trial sites, and interviews
were conducted by independent interviewers by
telephone in accordance with a semistructured
interview guide. Both interviewers and participants
were blinded to treatment assignment. Qualitative
analysis was conducted using ATLAS-ti version 7.5,
and descriptive statistics were computed and
summarized.
Findings: Across 3 countries, 41 participants were
interviewed. Difficulty maintaining blood glucose
within a desired range, described by participants as
lack of blood glucose “stability,” was the most
concerning symptom that they reported, wanting to
see it improved during the clinical trial because it
negatively impacted their physical, mental, and
emotional lives. Participants who reported symptom
improvement also reported a positive psychosocial
impact while taking the clinical trial medication. All
participants who monitored ketones described* Current affiliation: Guest Lecturer, Royal Holloway,
University of London.themselves as being “pretty confident” to “very
confident” that they could avoid diabetic ketoacidosis
by monitoring both ketone levels and understanding
the physical signs and symptoms of hyperglycemia.
Implications: Improvements in glucose stability and
control were important to participants with type 1
diabetes, as these improvements were correlated with
improvements in the participants' lives. ClinicalTrials.
gov identifiers: NCT02384941; NCT02421510. (Clin
Ther. 2019;41:2219e2230) © 2019 Published by
Elsevier Inc.
Key words: exit interview, sotagliflozin, SGLT in-
hibitor, type 1 diabetes.INTRODUCTION
The clinical importance of glycated hemoglobin A1c
levels in diabetes has been well documented1e3;
however, little is understood about the impact of
glycemic variability from the patient's perspective. In
a recent conjoint analysis, the amount of time in the
ideal glucose range of “most of the day” was the
strongest driver of participants' choosing one therapy
over another.4 With the increased availability of
continuous glucose monitoring allowing a detailed
assessment of glucose fluctuations, clinicians andAccepted for publication September 3, 2019 https://
doi.org/10.1016/j.clinthera.2019.09.003 
regulatory bodies are challenged to consider glycemic
stability in addition to A1c levels.
Two Phase III clinical trials of sotagliflozin (200 or
400 mg once daily) as an adjunct to insulin therapy
for patients with type 1 diabetes (T1D) with
inadequate glycemic control, inTandem15 and
inTandem26 (hereafter referred to as clinical trials
309 and 310), were recently completed. The primary
end pointdefficacy at both dosages versus
placebodwas met, as measured by statistically
significant reductions in A1c at week 24. Additional
benefits of sotagliflozin over placebo included a
greater time spent in the target glucose range,
reduction in total insulin dose, and reduction in
blood pressure. Participant-reported outcomes
(PROs) data from clinical trials 309 and 310 showed
increased treatment satisfaction, and reduced stress,
as measured by the Diabetes Distress Screening Scale,
among patients in the sotagliflozin arms compared
with those in the placebo arms.5,6
To better understand the experiences associated
with T1D and the importance of any changes
experienced by patients during these studies, a
qualitative interview study was conducted in a subset
of patients who participated in trials 309 and 310.
PATIENTS AND METHODS
Study Design
Individual participant interviews were conducted in
a subset of participants in clinical trials 309 (United
States and Canada; ClinicalTrials.gov identifier:
NCT02384941) and 310 (United Kingdom;
ClinicalTrials.gov identifier: NCT02421510).
Specifically, all eligible patients (regardless of
treatment assignment, inclusion criteria below) from
participating clinics were invited in a sequential,
consecutive manner (by date of study exit) to
participate in an interview. Each interview was
conducted by telephone by a dedicated study-specific
(309 or 310) interviewer and lasted ~60 min.
Interviews followed a semi-structured interview guide
designed to provide structure to the interviews by
ensuring that data were collected in a systematic and
consistent way and that interview objectives were
met. The interview was composed of qualitative
(open-ended, descriptive) questions and quantitative
(closed ended) questions. These quantitative
assessments were read aloud to each interview
participant and answered during the interview.All parties were blinded to treatment assignment at
the time of the interview. Investigators were unblinded
to data during the data analysis phase. All procedures
and materials for this study were approved by RTI
Health Solutions' institutional review board (IRB;
United States), by Chesapeake IRB (Canada), and by
HRA Ethics (United Kingdom). All interview
participants provided verbal consent prior to the
interview.
Inclusion Criteria
To be eligible for inclusion in this study, participants
had to have completed, or have discontinued early
from, clinical trial 309 or 310 at <12 months prior
to interview scheduling, and be able to speak, read,
and comprehend English. There were no exclusion
criteria.
To facilitate participant recruitment, a
comprehensive list of eligible participant numbers
(IDs) per participating clinic was generated and
provided to each of the participating clinical trial
sites. To limit bias in sample selection, the participant
lists included all participants, regardless of
randomization assignment. Site staff contacted
eligible participants on the list by telephone, starting
with those who had most recently exited the study.
Clinic staff then described the interview study to the
participants using IRB-approved recruitment
materials, and referred interested participants to the
appropriate interviewer for the scheduling of an
interview.
Interview Methods
Each interview was conducted according to a
semistructured interview guide and was audio-
recorded with participants' permission. The guide
contained both qualitative (open-ended) questions to
allow for spontaneous reporting, with targeted
probes to ensure that specific research objectives were
met, and quantitative (closed-ended) questions.
During the interviews, participants were asked to
describe their pretrial experiences (symptoms and
impacts) with T1D, their experiences during the
clinical trial after randomization, as well as their
satisfaction with T1D treatments. Participants were
asked to report the T1D symptom that most
concerned them, and the symptoms they most wanted
to see treated with an effective T1D medication.
Participants were questioned on their experiences
during the clinical trial and what changes, if any, they
noticed during the trial. Participants who reported >1
treatment benefit were asked to identify the most
important treatment benefit they experienced during
the clinical trial, and to describe why that benefit was
so important to them. All participants who reported
any treatment benefit during the clinical trial were
asked to discuss the potential impact(s) of those
benefit(s). Participants were asked to rate their
satisfaction with treatment before and during the
clinical trial, on a 7-point scale ranging from 0 (very
dissatisfied) to 6 (very satisfied). This scale was
similar to the global satisfaction scale included in the
Diabetes Treatment Satisfaction Questionnaire
(DTSQ)7 used for collecting PRO data during clinical
trials 309 and 310.
Analysis Methods
A thematic analysis method was applied to analyze
the interview field notes and transcripts.8 Important
concepts and dominant trends in each interview were
identified and then compared across interviews to
allow for the generation of themes or patterns in
participants' responses. Participants' experiences and
perceptions of change and treatment benefit over the
study period were then described. The analysis was
facilitated by coding software (ATLAS-ti version 7.5;
Scientific Software Development, Berlin, Germany),
and the initial coding framework was developed and
adapted as the analysis progressed to incorporate
emerging themes.
Additionally, descriptive statistics based on the
quantitative data obtained during the interviews (eg,
symptom improvements during the clinical trial) were
computed and summarized (ATLAS-ti version 7.5).
RESULTS
From the 82 sites participating in the clinical trials, 9
US, 4 Canadian, and 7 UK sites participated in the
qualitative interview study. Of the 1575 participants
who were included in the clinical trials (trial 309,
N ¼ 793; trial 310, N ¼ 782) 72 participants (4.6%
of the total trial population) were eligible for the
interview study (ie, had exited the clinical trial from
1 of the 9 clinical trial sites participating in the
interview study, within the previous 12 months). Of
these, 31 decided not to participate (reasons for
nonparticipation were not collected). Interviews were
scheduled with all 43 remaining participants, 41 ofwhich were completed, and 2 of which resulted in
nonattendance by the interviewee.
The demographic and clinical characteristics of the
study participants were similar to those of the overall
populations of clinical trials 309 and 310 (Table I).
Background and Pretrial Experiences With T1D
All 41 participants reported difficulty maintaining
their blood glucose within a desired range prior to
the clinical trials. This difficulty was commonly
described as frequent “high” (n ¼ 40) or “low”
(n ¼ 32) blood glucose events (hyperglycemia or
hypoglycemia, respectively). Thirty-seven participants
reported higher-than-desired A1c levels, and 35
participants also described a general lack of blood
glucose stability, as demonstrated by the following
sample quotes (participant number treatment
assignment; P ¼ placebo, Tx ¼ sotagliflozin): “Too
many lows, too many highs. Not enough time in the
zone,” (23_P); "[Blood glucose was] going high and
wanting to fall asleep in my tracks, and then 2 h
later starting to crash and starting to shake and
sweat, and all those great things that go with it,”
(21_Tx); “My sugar would keep bouncing around no
matter what I did. It would go high; it would go low.
It was not stable,” (03_Tx).
The most commonly reported “most concerning
symptom” of diabetes before the trial was frequent
high blood glucose events (n ¼ 12), followed by
higher-than-desired A1c levels (often ascribed to
blood glucose events by participants) (n ¼ 10),
hypoglycemia (n ¼ 8), and overall lack of blood
glucose stability (n ¼ 6). When asked why particular
symptoms caused the most concern, participants'
responses often centered on both the short- and long-
term negative health impacts that these symptoms
had, or could have, on their lives, as demonstrated
by the following sample quotes: “I guess the fear of
the long-term consequences of frequent highs,
specifically, like, on kidneys, eyes, feet, general
health,” (27_Tx); “I would have to say the fluctuation
in sugar levels [are the most concerning] … [being]
too high because basically if you're high, it's
shortening your life, putting you at risk. … But on
the same scale, a low is not healthy either because of
… the shock that the body goes through with the
adrenalin and the long-term effects of how it can
affect your memory and everything,” (25_P); “The
one that concerns me the most is the A1c levels
Table I. Demographic and clinical characteristics of the interviewed sample, eligible but did not participate













Male, no. (%) 24 (58.5) 14 (45.2) 383 (48.3) 406 (51.9)
Age, y
Mean (range) 48.1 (26e70) 42.9 (22e68) 46.1 (18e79) 41.2 (18e78)
At diagnosis, mean (range) 23.7 (1e54) 21.1 (1e47) 21.7 (0e69) 22.8 (1e66)
Years since diagnosis, mean (range) 24.3 (4e60) 21.8 (1e48) 24.4 (1e64) 18.4 (1e59)
T1D treatment mode prior to study
Insulin delivery, no. (%)
Injection 19 (46.3) 20 (64.5) 320 (40.4) 581 (74.3)
Pump 22 (53.7) 11 (35.5) 473 (59.6) 201 (25.7)
Use of CGM prior to study 10 (24.4) Not available Not available Not available
Treatment assignment, no. (%)
Active treatment 27 (65.9) 22 (71.0) 525 (66.2) 524 (67.0)
200 mg 11 (40.7) 11 (50.0) 263 (50) 261 (49.8)
400 mg 16 (59.3) 11 (50.0) 262 (50) 263 (50.2)
Placebo 14 (34.1) 9 (29.0) 268 (33.8) 258 (33.0)
Participated in CGM substudy, no. (%) 4 (9.8) 3 (9.7) 136 (17.1) 142 (18.2)
CGM ¼ continuous glucose monitor; T1D ¼ type 1 diabetes.
The clinical trial demographic and clinical characteristics used to populate this table were provided to Research Triangle
Institute Health Solutions (RTI-HS) by Lexicon.simply because that's an indication of your average
blood glucose level over time. And the higher your
A1c, the higher your blood glucose level and the
greater the risk for other complications,” (18_Tx).
Almost all participants (n ¼ 39) reported that T1D
had a negative impact on their life as seen in Table II.
Participants commonly described these impacts as
highly related. For example, the emotional impacts
(eg, irritability or depression) associated with T1D
symptoms often affected social and familial
relationships; the physical impacts (eg, fatigue,
shakiness) reduced participants' ability to accomplish
tasks at home or at work, as exemplified by the
following quote: “It [T1D] can make you depressed.
It can make you angry. It can make you irritable. It
can impact your ability to walk in a straight line. It's
constantly, you're constantly thinking about what are
you eating and how's that affecting your body
chemistry. And how's exercising … is exercise
impacting that. So let's just say that diabetes has apervasive effect on pretty much every aspect of your
life,” (18_Tx).
The most frequently reported impacts of T1D (with
sample quotes) included:
Physical impacts (eg, how one feels physically,
physical functioning, lower energy/increased
fatigue) (n ¼ 34): “When you have high blood
sugars, you definitely feel more lethargic and lazy
and do not want to do anything,” (07_Tx); “I am
just a little bit slower, a little bit more tired, get
tired faster,” (06_Tx).
Mood and emotional impacts (eg, depression,
anxiety, sadness) (n ¼ 31): “Like when your blood
sugar is high, you are a little more angry
sometimes, and you say get away from me; when
it is low, you get so down about everything
because you are just trying to get something to
eat, and you feel basically horrible, so it is like
from one rebound to the other, it is hard,”







Physical (eg, how one feels physically, physical functioning, energy
level/fatigue)
23 (85.2) 11 (78.6) 34 (82.9)
Mood/emotions (eg, depression, anxiety, sadness) 24 (88.9) 7 (50.0) 31 (75.6)
Daily activities in general (eg, exercise, self-care, travel, hobbies,
driving)
19 (70.4) 8 (57.1) 27 (65.9)
“Quality of life” (mentioned specifically) 14 (51.9) 5 (35.7) 19 (46.3)
Self-esteem (eg, self-confidence, how one feels about themselves) 11 (40.7) 4 (28.6) 15 (36.6)
Daily activities at work (impact on any gainful activities
[eg, absenteeism, productivity])
9 (33.3) 5 (35.7) 14 (34.1)
Social activities (eg, diminished desire or ability to participate in
social activities such as going out with friends, family)
6 (22.2) 6 (42.9) 12 (29.3)
Family/family planning 6 (22.2) 3 (21.4) 9 (22.0)
Mental clarity (impact on ability to think clearly or quickly;
fogginess)
3 (11.1) 4 (28.6) 7 (17.1)
Daily activities at home (impact on any non-gainful activities/
chores at home)
3 (11.1) 1 (7.1) 4 (9.8)
T1D ¼ type 1 diabetes.(14_Tx); “When I am having a lot of lows, I get
really emotional and cry a lot and then I say
things I do not mean. Then when I am having
highs I am angry, I get mad, like we are kids. Just
at the drop of a hat. That is mostly because your
whole body just does not feel right,” (08_P).
Activities of daily living (eg, exercise, self-care,
travel, hobbies, driving) (n ¼ 27): “I was really
scared to be driving and it [blood glucose] drop on
me. The highs, like I said, other than just being
really tired, I was not so scared to drive with
them. Lows, I would not drive. It would scare me.
I would be driving, and it would happen so I
would keep something in my car to cram [to eat],"
(03_Tx); “It prevented me from doing certain
things by limiting my energy and willingness to
participate,” (02_Tx).
Overall quality of life (n ¼ 19): “It affects everything
in my life I feel. It has affected my decision to have
children, it affected how old I think I am going to
live to be, my quality of life and my day to day,
every day, everything I am doing. Everything kind
of wears on you up to a certain point,” (02_Tx);“It [T1D] … it consumes my life. My whole life
revolves around it,” (08_P); "It's [T1D] life
changing … It really is. It changes your life.
Basically, if I don't inject the insulin, I die,” (39_P).
Full participants' descriptions of the impact of T1D
in different domains are shown in Supplemental
Table I (see online version at https://doi.org/10.1016/
j.clinthera.2019.09.003).
Treatment Desires
When asked what specific symptom participants
most wanted to see treated/improved in the clinical
trial, lack of stable blood glucose was most
commonly reported (n ¼ 16), followed by higher-
than-desired A1c (n ¼ 15), and frequent
hyperglycemic events (n ¼ 7) (Table III). When asked
why improvement in these symptoms was so desired,
responses included that these improvements could
reduce the risk for long-term consequences, improve
quality of life, and make them feel in control of their
blood glucose: “If I get my blood sugar under control
and I have my weight down, then I'll be happy.
Table III. Frequency of symptoms that participants most wanted to see treated in clinical trials. Data are given
as the number (%) of patients.






Lack of stable blood glucose 10 (40.0) 6 (50.0) 16 (43.2)
Higher than desired A1c 9 (36.0) 6 (50.0) 15 (40.5)
Weight gain 2 (8.0) 4 (33.3) 6 (16.2)
Frequent hypoglycemic events 0 4 (33.3) 3 (8.1)
Increased use of insulin over time/less effective insulin 3 (12.0) 2 (16.7) 5 (13.5)
Frequent hyperglycemic events 6 (24.0) 1 (8.3) 7 (18.9)
General health 1 (4.0) 0 1 (2.7)[Better glucose control means] what I'd like to see is
have my sugars more often in the target range,”
(38_Tx); "[Glucose instability] affects my life more
than anything to go from being really high to being
really low and then a lot of the time go really high
again. It just affects the way I feel,” (12_Tx);
"[Hyperglycemia] Probably those occasional highs.
Why was that really what you wanted to see
improve? Just to get rid of that lethargic tired
feeling,” (16_Tx).
Experiences During the Clinical Trials
The frequencies of reported symptom improvement
over the course of the clinical trials are shown in
Table IV, and selected participants' descriptions of
improvements in their symptoms are shown in
Supplemental Table II (see online version at https://
doi.org/10.1016/j.clinthera.2019.09.003). Of the 41
participants, 33 (80.5%; 26 on sotagliflozin, 7
placebo) reported improvements in at least 1
symptom. The most frequently reported
improvements included fewer hyperglycemic events
(n ¼ 31), increased blood glucose stability (n ¼ 30),
more effective/reduced insulin use (n ¼ 28), lower
A1c (n ¼ 28), and fewer hypoglycemic events
(n ¼ 17) (see Table IV).
When asked to rate the importance of improvements
on a scale of 1e5 (Figure), greater blood glucose
stability (mean, 4.7) and reductions in A1c levels
(mean, 4.6) were rated as the most important
improvements, closely followed by (and described as
highly related to) reductions in “high” (mean, 4.5)
and “low” (mean, 4.4) blood glucose events.
More than half of the participants noted that 3
specific improvements experienced during the clinicaltrial were “very” or “extremely” important (Figure):
fewer hyperglycemic events, greater blood glucose
stability, and reduced A1c levels. When asked to
describe why these improvements were so important,
a typical participants' response was: “I guess the
insulin going down would be the most important,
with the blood sugar levels being more stable.” Why
are those 2 really the most important? “Well, it
affects your whole body, it affects your weight, it
affects you mentally, just everything. Once you get
those going down … if you maintain that high, you
lose focus, you start losing everything, you start
gaining weight. The most important thing is getting
that blood sugar level [stabilized]," (06_Tx).
All but 1 (97%) of the interview participants who
reported symptom improvement also reported that
these improvements had a positive impact on their
lives. These positive impacts included improvements
in mood/emotions (n ¼ 23), physical functioning
(n ¼ 16), self-esteem (n ¼ 11), overall quality of life
(n ¼ 9), and a greater ability to accomplish activities
(both in general [n ¼ 6], and at work/home [n ¼ 6]).
Participants typically described these positive impacts
as follows: “I felt better about myself. About how the
study was going. It made me feel good that all these
things were happening. You always have that
thought … I have these high blood sugars, and I have
this low blood sugar, and it is like a complete 180
when I was on it [study medication]. Consistently
better so you do not have to worry as much,”
(07_Tx); “Yes, my sugars went down … Then of
course with my sugars going down my A1c went
back into a better range. Other than not having highs
and high symptoms, I just felt better … I was not
tired as much. I actually started walking again too
Table IV. Frequency of reported symptom improvement over the course of the clinical trials. Data are given as
the number (%) of patients.






Fewer hyperglycemic events 24 (88.9) 7 (50.0) 31 (75.6)
Active treatment 24 (58.5)
Placebo 7 (17.1)
Increased blood glucose stability 24 (88.9) 6 (42.9) 30 (73.2)
Active treatment 24 (58.5)
Placebo 6 (14.6)
Reduced insulin/improved 21 (77.8) 7 (50.0) 28 (68.3)
Active treatment 21 (51.2)
Placebo 7 (17.1)
Lower A1C 23 (85.2) 5 (35.7) 28 (68.3)
Active treatment 23 (56.1)
Placebo 5 (12.2)
Fewer hypoglycemic events 14 (51.9) 3 (21.4) 17 (41.5)
Active treatment 14 (34.1)
Placebo 3 (7.3)
Weight loss 14 (51.9) 2 (14.3) 16 (39.0)
Active treatment 14 (34.1)
Placebo 2 (4.9)
Lower blood pressure 3 (11.1) 0 (0) 3 (7.3)
Active treatment 3 (7.3)
Placebo 0 (0)
Reduced neuropathy 1 (3.7) 1 (7.1) 2 (4.9)
Active treatment 1 (2.4)
Placebo 1 (2.4)
Less extreme highs and lows in blood glucose 3 (11.1) 1 (7.1) 4 (9.8)
Active treatment 3 (7.3)
Placebo 1 (2.4)when my daughter was at dance and things like that,”
(08_P).
In general, participants who saw a reduction in the
number of hypoglycemic events also reported feeling
more confident about not having them.
Of the 41 interviewees, 2 described experiencing
diabetic ketoacidosis (DKA) during the clinical trial.
When probed about ketone monitoring and fear of
DKA, about half of the participants (n ¼ 20; 48.8%)
reported undergoing at least occasional monitoring
both before and during the clinical trial. Participants
reported experience with both urine and/or blood test
strips, and most commonly described the process aseasy to do. All participants who monitored ketones
reported some level of confidence that they could
avoid DKA by monitoring both ketone levels and
understanding the physical signs and symptoms of
hyperglycemia.
Treatment Satisfaction
During the interview process, participants from the
active treatment group (n ¼ 27) rated their
satisfaction as higher than before the trial (5.5 vs 3.9,
see Table V). Participants from the placebo group
(n ¼ 14) rated their satisfaction during the trial as
lower than before the trial (3.7 vs 4.3). Participants'
Figure. Frequency of reported T1D symptom improvements and importance ratings (N ¼ 41). Importance
rating scale: 1 ¼ not at all important; 2 ¼ a little important; 3 ¼ moderately important; 4 ¼ very
important; 5 ¼ extremely important. The numbers above each bar indicates the total number of par-
ticipants who reported a specific symptom improvement. The numbers in the darker shaded area of
each bar indicate the number of participants who reported their improvement as “very” or “extremely”
important. Hb ¼ hemoglobin; T1D ¼ type 1 diabetes.
Table V. Interview and clinical trial treatment satisfaction scores* before and during the clinical trials. Data are
given as mean (range).
Treatment Group Interview Questions: Satisfaction Clinical Trial Questions: DTSQ Item 1
Before During Baseline Week 24
Active treatment (n ¼ 27) 3.9 (0e6) 5.5 (3e6) 4.2 (1e6) 5.1 (0e6)
Placebo (n ¼ 14) 4.3 (3e5) 3.7 (0e6) 4.1 (3e5) 3.8 (0e6)
All patients (N ¼ 41) 4.0 (0e6) 4.9 (0e6) 4.2 (1e6) 4.7 (0e6)
* Participants were asked to rate their satisfaction with treatment before and during the clinical trial, on a 7-point scale ranging
from 0 (very dissatisfied) to 6 (very satisfied).reasons for increased satisfaction during the trial were
directly related to the symptom improvements that
they experienced and the positive impact those
improvements had on their overall well-being, asexemplified by the following answers to the question,
“What specifically influenced your response to say
that it was a [6]dthat you were very satisfied?”:
“Everything. The weight loss, the consistency in my
blood sugars, everything. It was amazing. The part that
really sucked about it was when it was over,” (07_Tx);
“Because my whole outlook and the way I felt, felt so
much better. You feel that you have a better quality
of life. You can participate. … You lost weight, your
sugars went down, you felt so much better. I really,
really loved it,” (06_Tx).
Similarly, a higher proportion of patients on active
treatment (88.9%) than placebo (42.9%) stated that
theywould have continued studymedication (Table VI).
Adverse Events
Although not specifically probed during the
interviews, a total of 19 potential adverse events were
recalled by 12 participants. Of these, all but 1 (gas)
had previously been reported during the clinical trial.
No new tolerability signals were identified.DISCUSSION
This study is one of the first to capture participants'
own voices describing the general burden of T1D in
their lives, their hopes for a new therapy before
initiating it, and their subjective experiences and
descriptions of symptom changes while on therapy.
These qualitative data provide a valuable supplement
to the efficacy and tolerability data derived from the
clinical trials themselves,5,6 giving insights into the
trial participants' own perceptions of the benefits of a
dual sodiumeglucose cotransporter 1 and 2 inhibitor
as a therapy to adjunct insulin, which may not be
captured sufficiently by conventional clinical and
participant-reported end points. Asking “why”
participants expressed their opinions and choices, in
addition to “what” they feel they achieved during the
clinical trial, enriches our understanding of the
participants' experience. An important development
in PRO studies, as regulatory bodies, payers, and




Active Treatment (n ¼ 27)
Yes 24 (88.9)
No 2 (7.4)
Unsure 1 (3.7)interested in determining the participants' perspective
on the overall riskebenefit profile of a drug.9
This study yielded a number of important insights in
addition to the findings of the clinical trials.
Participants consistently reported the value of glucose
stability and control, which is in accordance with
findings from previous literature on the importance
of glycemic stability to participants with T1D.10,11
Glycemic fluctuations are seen as postprandial
glycemic spikes and minor hypoglycemia. A study
analyzing data across the United Kingdom, the
United States, and Germany found that 61.5% of the
study population had experienced postprandial
hyperglycemia in the previous week.12 Glycemic
variability is known to be associated with mood
changes, anxiety, and absenteeism (inability to
work).13,14
The findings from this study add a new dimension to
the body of evidence by allowing participants to
discuss this in an unprompted manner, using their
own words. Interpretation of quantitative PRO
measures or those reliant on Likert scales (always/
sometimes/often/never) may be affected by participant
habituation effectsdin which participants grow
accustomed to their condition and so rate the effects
as less severe. By recording detailed descriptions of
life experience with T1D, we were able to record a
clearer picture of the effects of treatment on
participants' well-being.
The majority of the participants who described
improved glycemic control during the trial clearly
articulated that the change was meaningful and had a
positive impact on their lives. These positive impacts
spanned several domains of well-being, including
mood/emotions, physical functioning, self-esteem, and
improvements in overall quality of life. The positive
impacts on the lives of patients provide important
insights into the relevance of end points, including
time in range and patient reported outcomes. Thesen after the trials. Data are given as the number (%) of
Placebo (n ¼ 14) All Patients (N ¼ 41)
6 (42.9) 30 (73.2)
8 (57.1) 10 (24.4)
0 1 (2.4)
end points can support informed discussions and
participant-support initiatives.
People reported their satisfaction from clinical trials
309 and 310 during the interviews at levels similar to
those from the DTSQ at the time that the trial was
being conducted. This finding suggests that their
quantitative perception recall of treatment was valid.
In participants on active treatment, increases in
satisfaction from before the trial to during the trial,
on both the survey during the interview and on the
DTSQ, related to the symptom improvements that
they experienced and the positive impact that those
improvements had on their overall well-being. The
improvement in well-being has potentially important
implications for adherence and persistence. These
results suggest that sotagliflozin provides an
important treatment benefit in participants due to its
ability to improve glycemic control.
Gaining a deeper insight into the participant
perspective helps us to understand the variables
associated with participants' personalized decision-
making processes, particularly their perceptions of
the benefits and risks of therapy that manifest in their
overall satisfaction that was captured within the trial
and during the exit interviews. When questioned
about the risks of DKA, the study results suggest that
participants understood the risks involved, and did
not find ketone monitoring to be burdensome, but
regarded it as an acceptable procedure given the
benefits of therapy.
Strengths and Limitations
The strengths of this study included recruiting all
eligible participants regardless of their treatment
status or completion of the 52-week trial, and
keeping both participants and interviewers blinded to
treatment assignment during the interview. Prior
experience interviewing subjects in clinical trials has
shown that clinically meaningful experiences can be
captured with as few as 20 participants.15 This
precedent was a consideration when determining the
sample size of this study.
There is potential for selection bias in interview
studies; however, similarities in baseline
characteristics and proportion of placebo participants
between interview participants and the overall clinical
trial provided reassurance that selection bias may
have been minimal. Additionally, although 41
participants is a small percentage of the total trialpopulation, this is not unusual for exit interviews.
Mean DTSQ scores at the end of the interview study
and clinical trial also appeared to be similar,
reflecting the proper selection of participants without
regard to participant response.
To examine the potential for recall bias, satisfaction
scores from interviews were compared to those
obtained during the trial. The context of presenting
these questions was different for the 2 settings, the
items themselves were slightly different, and
differences in results do not necessarily suggest a lack
of recall. Nonetheless, some relevant findings were
evident. The mean baseline satisfaction scores on the
DTSQ, reported in the context of the clinical trial,
were slightly higher than what was recalled for
pretrial experiences during the interview, but there
was still a relatively strong correlation between the 2
ratings (0.62). There was a very strong correlation
(0.90) between DTSQ scores at the end of the trial
(week 24) and interview reports of satisfaction during
the trial. There are several possible explanations for
the similarities in clinical trial and interview ratings
of satisfaction. It is possible that participation in the
interviews occurred soon enough after study
completion for participants to accurately recall their
experiences. Additionally, it is possible that
satisfaction reports were similar because the benefits
were meaningful (and therefore not forgotten), or
because the loss of benefits in the months after study
completion reinforced the memory of the clinical
trial. The close similarities between these interview
results and DTSQ scores at the end of the clinical
trial suggest that participants were able to recall their
clinical trial experiences accurately.
CONCLUSIONS
In this interview-based study, participants with T1D
reported that improvements in glycemic stability and
control were the most meaningful to them due to
improvements to their physical functioning, self-
esteem, and overall quality of life.
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APPENDIX A. BURDEN OF T1D AND PARTICIPANTS' DESCRIPTIONS OF IMPACTS PRIOR TO


















11 (78.6) 23 (85.2) 34 (82.9) Walking, exercising. It is hard because [inaudible] exercising
is really difficult. (11_Tx)
Because you get sweaty and the shakes and you know your
blood sugar is getting low, but the longer you have it, those
symptoms do not appear right away. (07_Tx)
When you have high blood sugars, you definitely feel more
lethargic and lazy and do not want to do anything.
(07_Tx)
I am just a little bit slower, a little bit more tired, get tired
faster as you get older, I guess that comes with it. (06_Tx)
Dry skin first, headaches, when my sugar is low I get shaky
and feel really bad. (12_Tx)
I get really tired, really bad headaches, just do not want to
move, do not want to do anything. If it is extremely high,
then I get sick to my stomach. (03_Tx)
Physically I noticed I was very tired. I was needing sleep. I
always wanted to sleep. I looked forward to Saturdays so I
could sleep till 9 or 10:00. I just, I was just sleepy. And
I'd go to bed and just hit the pillow and I'd be out.
(15_Tx)
For a low sugar hypoglycemic episode, I would become very
sweaty, agitated, sometimes nauseous or have headaches,
become obsessed with food and eating. I would try to eat
something quickly so that I felt better… With the highs,
dry cotton mouth, headache, sometimes nauseous if they
were very high, lethargic. (10_P)
When your sugar is always high, you are a lot more tired,




7 (50.0) 24 (88.9) 31 (75.6) Just the hassle of constantly checking, worrying if it is too
high, too low… Yes. Worrying I am going to pass out and
die from the lows. I had a friend that happened to. Am I
going to do it if my grandchildren are here? That scares
me. (03_Tx)
Higher stress and some depression. (02_Tx)
It does affect them; it is like when your blood sugar is high,
you are a little more angry sometimes, and you say get
away from me; when it is low, you get so down about
(continued on next page)
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everything because you are just trying to get something to
eat, and you feel basically horrible, so it is like from one
rebound to the other, it is hard. (14_Tx)
It has been very hard because there are times when I am very
emotional. When I am having a lot of lows, I get really
emotional and cry a lot and then I say things I do not
mean. Then when I am having highs I am angry, I get
mad, like we are kids. Just at the drop of a hat. That is
mostly because your whole body just does not feel right
and then somebody is doing something that is making you
mad and I just… not snap, but I have a trigger. I get mad
easier. (08_P)
I'm a dad with 2 kids who are now teenagers. So it's the
emotional impact of having them watch me go through
this and my spouse. The lack of being able to be the father
at times that I want to be. And to hear that this being a
genetic disease, they are predisposed to following my path,
which is not something I want. We waited 8 years to have
kids because I had to get over the mental hurdle of ‘what
if.’ (23_P)
Even if it's just going to the beach for the day with the dog.
You've got to think about when you eat, when you inject,
how long are you going to be out… It does make a
difference. (39_P)
I think the thing is that it affects my life 24/7. It's a
constant thought, pretty much. There won't be an hour in
the day, or a half hour in the day, that I don't think about
my diabetes. If I go out for a walk, I have to be aware that






8 (57.1) 19 (70.4) 27 (65.9) I was really scared to be driving and it drop on me. The
highs, like I said, other than just being really tired, I was
not so scared to drive with them. Lows I would not drive. It
would scare me. I would be driving, and it would happen
so I would keep something in my car to cram [to eat].
(03_Tx)
It prevented me from doing certain things by limiting my
energy and willingness to participate. (02_Tx)
I am very routine. It is very hard for me to get out of a
routine. I eat dinner at the same time, I eat lunch at the
same time. So, when you work, I am a normal adult,
working. It is just in my life, it consumes my life. My whole












And I hate that [T1D] is the first thought that comes in my
mind before I want to go out, before I want to go to the
gym, before I want to do something with my kids, before I
travel, before anything. It's the check, it's the how are
you, it's the fear that something happens while you're
then trying to go about your day and trying to be prepared
for it and manage it to the best of your abilities. But
knowing that you can't always succeed. (23_P)
Quality of life 5 (35.7) 14 (51.9) 19 (46.3) It affects everything in my life I feel. It has affected my
decision to have children, it affected how old I think I am
going to live to be, my quality of life and my day to day,
every day, everything I am doing. Everything kind of wears
on you up to a certain point. (02_Tx)
It is a mix of things, it is everything from, is this [T1D] going
to kill me in the next 10 years? How am I going to
continue to get medicine? Did I not get that job because I
am diabetic? Did I not do this thing? Yes, it affects
everything. Does it bum people out? Does this keep people
at a distance? (05_P)
I mean would it be different if I didn't have to think about
it? Would it be easier if I didn't have diabetes?
Absolutely. But quality, I think I have a pretty good
quality of life. But would it be easier? Yeah. I mean like
even something as simple as traveling and having the extra
stuff to take or trying to get on the plane with syringes and
vials of insulin and doctor's notes and all that medication.





4 (28.6) 11 (40.7) 15 (36.6) I would say the lack of education of others is actually very
impactful on your self-esteem and your mental state and
how you feel about yourself. (35_Tx)
I am a perfectionist, and in school I always had to be the
straight-A student, and diabetes feels like I have been
given a test and I am failing. (12_Tx)
I think I am very hard on myself when it comes to that. I do
not think I say it, but I feel it inside. I do not really voice it,
but I know I am disappointed in myself a lot because of it.
Then of course, my weight too. I would love to be back like
I was in my 20s but that is not going to happen. (08_P)
Sadly, it probably defines you. It defines me first and
foremost and again, I hate that. But everything I do has to
be done with that in the back of your mind first. (23_P)


















5 (35.7) 9 (33.3) 14 (34.1) Yes, I would say the shaky feeling. The unsteady feeling
impacts my work life. (12_Tx)
And there have been times when if I'm at work and my
blood sugar drops, and if I'm dealing with somebody or
I'm in a meeting or something's happening and my blood
sugar drops, I feel … the only way I describe it as it like
cotton brain. Where everything's kind of clouded, and it's
hard to piece words together and sentences together
properly. (29_P)




desire or ability to
participate in
social activities
such as going out
with friends,
family)
6 (42.9) 6 (22.2) 12 (29.3) Oh, I was really down and depressed and you couldn't do
this and a lot of things we used to do and eat and I felt
like an outsider. And especially, I was working … And
they would have like lunches or like they had Marble Slab
ice cream one day come into the school and you could have
your own sundae and all this. And I didn't get to partake
because I have diabetes. I always felt left out. I mean just
stuff like that where I felt left out and not included, so.
(15_Tx)
Just that everything you do is harder. I never discuss it with
anybody, so no one really knows because I do not bring it
up in conversation. Obviously in your inner circle. Just
remember one thing in life, people do not want to know
what is wrong with you, they want to know what is right
with you. So, you find a way to try to deal with it and keep
it to yourself. (13_Tx)
I would like to drink more. I would like to be able to order
an adult cocktail and not have to worry about what it is
going to do, how much insulin do I take? I would like to
just have a normal adult life. (08_P)
You cannot just go out and go to dinner with your friends
and just have the filet mignon and a side of potatoes; you
have got to think, well I will have the filet mignon, but
maybe I should have vegetables instead of the potatoes.
Or everybody is going to sit down with pie and coffee and
you are sitting there maybe with a plain piece of cake if
you can get away with it [inaudible] you do not have pie,
you just have coffee. So, it is always something that singles














3 (21.4) 6 (22.2) 9 (22.0) Probably the snippiness with my family affects me the most
just because it puts a strain on the relationship with my
wife. That would probably be the biggest. (7_Tx)
It has affected my decision to have children (02_Tx)
Mental clarity due
to low or high
blood glucose
4 (28.6) 3 (11.1) 7 (17.1) You get kind of snippy with people, or you forget to do things.
It is just that you do not feel right. (07_Tx)
Yes, the mental fogginess, the whole body feeling draggy, you
just have no energy, the muscles ache. Everything. That is
the best way. (12_Tx)
It is difficult to think, difficult to speak. (05_P)
I was just sitting around, but I get kind of blank (01_P)
Daily activities at
home




1 (7.1) 3 (11.1) 4 (9.8) Like I said, except for during a high. I would not have any
energy and there were plenty of things I wanted to do or
needed to do. Especially at home, I just could not do them
… painting, or even sweeping and mopping. Just no energy
to do it. (06_Tx)
I make sure that I am not exerting myself too much because I
would have to stop every hour or hour and a half and go
get something to eat. Even at home when I am doing
chores around the house, if I start sweating and within the
hour my blood sugar is low, I have to go and eat
something. (07_Tx)
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My blood sugar was lowered. (02_Tx)
Yes, my sugars went down. Which was what the pill was supposed to do. (08_P)
I really felt like it was cutting down the spikes that I might have. (33_Tx)
Increased blood
glucose stability
Because that level stayed level instead of going up and down. There was more of a level there.
(06_Tx)
My sugars were more stable. I had fewer spikes. (12_Tx)
It did seem like I was in the good zone more often. (25_P)
I got longer periods [of stability] and more stable. (32_Tx)
I had more normal range blood sugars, which is just great. (40_Tx)






[I] was probably taking 60 units a day, and that dropped to 40. So that was the first thing that I
really saw, the insulin dosages going down. (06_Tx)
They started lowering my insulin dose I was taking. (03_Tx)
Lower A1C I had my absolute best A1C ever while doing that study. (31_Tx)
I started the program, it was 9, it changed, and then really at the conclusion of [the trial], it was
7. (13_Tx)
My A1C came down to the levels that we wanted it to be at. (12_Tx)
Fewer hypoglycemic
events
I think I had less lows when I was on the study. (15_Tx)
I think I had fewer incidents of low blood sugar as well. (33_Tx)
Weight loss But while on the trial, I did notice that I lost weight even if I was eating the same amount of food
or eating healthy, I just lost more weight, a significant amount while on the trial. (19_P)
I think I lost about 7 pounds. (11_Tx)
I was 275 when I started the study, and at the end of the year, I weighed around 250. (07_Tx)
Lowered blood
pressure
It seemed to get lower and a little bit more consistent as the trial went on. (33_Tx)




When the highs occurred, they were not as high. (16_Tx)
I would just say that the overall, the highs weren't quite as out of control. Like, sometimes when
you get a high, it's just, like, off the wall high, like you're looking at 22 type of thing. And it just
seemed like things were just a little tighter. Like, if I had a high, it wasn't crazy high. (25_P)
The peaks and valleys certainly reduced the frequency and they weren't as extreme. (21_Tx)
